Literature DB >> 17088471

Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib?

Keith Barnard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17088471

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  4 in total

1.  Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.

Authors:  Mitsukuni Suenaga; Nobuyuki Mizunuma; Kokoro Kobayashi; Eiji Shinozaki; Satoshi Matsusaka; Keisho Chin; Yasutoshi Kuboki; Takashi Ichimura; Masato Ozaka; Mariko Ogura; Yoshimasa Fujiwara; Kiyoshi Matsueda; Fumio Konishi; Kiyohiko Hatake
Journal:  Med Oncol       Date:  2009-08-21       Impact factor: 3.064

2.  COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.

Authors:  Piet Borgdorff; M Louis Handoko; Yeun Ying Wong; Geert Jan Tangelder
Journal:  Open Cardiovasc Med J       Date:  2010-10-21

Review 3.  Takotsubo cardiomyopathy in cancer patients.

Authors:  Aakash Desai; Arish Noor; Saurabh Joshi; Agnes S Kim
Journal:  Cardiooncology       Date:  2019-07-01

4.  Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer.

Authors:  Thérèse H Franco; Ahmed Khan; Vishal Joshi; Beje Thomas
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.